By Michael Enright, Venkat Subramanian, Jeroen van den Berg
Following a successful IPO in April 2004, Biocon - India's foremost biotech company - is in the midst of an ambitious overhaul. Long dependent on revenues from the production of enzymes and generic drugs, the Company feels competitive pressures from within the country, as well as from other developing economies such as China. The Volume shows how the company's founder, Kiran Mazumdar-Shaw, intends to take the company to the next level by transforming Biocon from a producer of generics into India's first true innovator in the field of biotechnology.
|